Trial reportBritish journal of cancer2006
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Trial report in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 71 citations in OpenAlex.
- Trial
- Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.Investigational new drugs · 2010Trial
- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Trial
- Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics.Pharmaceutics · 2020Article
- Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways.OncoTargets and therapy · 2020Article
- Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects.Journal of gastrointestinal oncology · 2018Review
- Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?OncoTargets and therapy · 2018Review
- Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.Oncology letters · 2017Article
- Pancreatic cancer: New hopes after first line treatment.World journal of gastrointestinal oncology · 2016Review
- Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest.Oncology research · 2016Article
- Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma.Journal of gastrointestinal cancer · 2015Article
- High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFPAC-1 cells through the EphrinB1-EphB2 pathway.Oncology letters · 2014Article
- FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.BMC cancer · 2014Article
- Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?World journal of gastroenterology · 2014Review
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Review
- Role of taxanes in pancreatic cancer.World journal of gastroenterology · 2012Article
- Overcoming drug resistance in pancreatic cancer.Expert opinion on therapeutic targets · 2011Review
- Systemic therapy for metastatic pancreatic adenocarcinoma.Therapeutic advances in medical oncology · 2010Article
- A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.British journal of cancer · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the patients present good performance status (PS) and are candidate for further treatment. Patients >18 years, PS >or=50, with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and progression-free survival (PFS) <12 months received a combination of raltitrexed (3 mg m(-2)) and oxaliplatin (130 mg m(-2)) every 3 weeks until progression, toxicity, or a maximum of six cycles. A total of 41 patients received 137 cycles of chemotherapy. Dose intensity for both drugs was 92% of the intended dose. Main grade >2 toxicity was: neutropenia in five patients (12%), thrombocytopenia, liver and vomiting in three (7%), fatigue in two (5%). In total, 10 patients (24%) yielded a partial response, 11 a stable disease. Progression-free survival at 6 months was 14.6%. Median survival was 5.2 months. Survival was significantly longer in patients with previous PFS >6 months and in patients without pancreatic localisation. A clinically relevant improvement of quality of life was observed in numerous domains. Raltitrexed-oxaliplatin regimen may constitute a treatment opportunity in gemcitabine-resistant metastatic pancreatic cancer. Previous PFS interval may allow the identification of patients who are more likely to benefit from salvage treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.